CLINICAL TRIALS PROFILE FOR MEASURIN

All Clinical Trials for Measurin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00983580 ↗	Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2009-08-20	This phase II trial is studying how well giving acetylsalicylic acid together with eflornithine works in treating patients at high risk for colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of acetylsalicylic acid and eflornithine may prevent colorectal cancer.
NCT02123849 ↗	Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers	Completed	National Cancer Institute (NCI)	Phase 2	2014-06-01	This randomized phase II trial studies the safety and effects of acetylsalicylic acid (aspirin) taken continuously or intermittently on gene expression in the nasal tissue of current smokers. Smokers are at increased risk of developing lung cancer. Acetylsalicylic acid may be useful in preventing lung cancer.
NCT02169271 ↗	Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules	Completed	National Cancer Institute (NCI)	Phase 2	2014-11-21	This randomized phase II trial studies acetylsalicylic acid compared to placebo in treating high-risk patients with subsolid lung nodules. A nodule is a growth or lump that may be malignant (cancer) or benign (not cancer). Chemoprevention is the use of drugs to keep cancer from forming or coming back. The use of acetylsalicylic acid may keep cancer from forming in patients with subsolid lung nodules.
NCT02348203 ↗	Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers	Completed	National Cancer Institute (NCI)	Phase 2	2016-01-13	This randomized phase II trial studies the effects of aspirin and zileuton on genes related to tobacco use in current smokers. Aspirin and zileuton may interfere with genes related to tobacco use and may be useful in preventing lung cancer in current smokers.
NCT02420652 ↗	Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy	Terminated	National Cancer Institute (NCI)	Phase 2	2015-06-23	This randomized phase II trial studies how well metformin hydrochloride and aspirin work in treating patients with hormone-dependent prostate cancer that has progressed after surgery or radiation therapy. Metformin hydrochloride and aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving metformin hydrochloride and aspirin together can slow the growth of prostate cancer.
NCT02420652 ↗	Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy	Terminated	Rutgers Cancer Institute of New Jersey	Phase 2	2015-06-23	This randomized phase II trial studies how well metformin hydrochloride and aspirin work in treating patients with hormone-dependent prostate cancer that has progressed after surgery or radiation therapy. Metformin hydrochloride and aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving metformin hydrochloride and aspirin together can slow the growth of prostate cancer.
NCT02420652 ↗	Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy	Terminated	Rutgers, The State University of New Jersey	Phase 2	2015-06-23	This randomized phase II trial studies how well metformin hydrochloride and aspirin work in treating patients with hormone-dependent prostate cancer that has progressed after surgery or radiation therapy. Metformin hydrochloride and aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving metformin hydrochloride and aspirin together can slow the growth of prostate cancer.

Clinical Trial Conditions for Measurin

Condition Name

Condition Name for Measurin
Intervention	Trials
Tobacco Use Disorder	3
Pulmonary Nodules	2
Dysplasia in Barrett Esophagus	1
Stage IIA Prostate Cancer AJCC v8	1

Condition MeSH

Condition MeSH for Measurin
Intervention	Trials
Tobacco Use Disorder	3
Prostatic Neoplasms	2
Multiple Pulmonary Nodules	2
Colorectal Neoplasms	2

Clinical Trial Locations for Measurin

Trials by Country

Trials by Country for Measurin
Location	Trials
United States	20
Canada	1
Italy	1

Trials by US State

Trials by US State for Measurin
Location	Trials
California	3
Texas	2
Massachusetts	2
Arizona	2
Minnesota	2

Clinical Trial Progress for Measurin

Clinical Trial Phase

Clinical Trial Phase for Measurin
Clinical Trial Phase	Trials
Phase 2	9

Clinical Trial Status

Clinical Trial Status for Measurin
Clinical Trial Phase	Trials
Completed	4
Active, not recruiting	3
Recruiting	1

Clinical Trial Sponsors for Measurin

Sponsor Name

Sponsor Name for Measurin
Sponsor	Trials
National Cancer Institute (NCI)	8
Rutgers Cancer Institute of New Jersey	1
Rutgers, The State University of New Jersey	1

Sponsor Type

Sponsor Type for Measurin
Sponsor	Trials
NIH	8
Other	4
Industry	2

Clinical Trials Update, Market Analysis, and Projection for Measurin

Last updated: October 28, 2025

Introduction

Measurin is an emerging pharmaceutical candidate developed for the treatment of chronic inflammatory diseases, notably rheumatoid arthritis (RA). Its unique mechanism centers on targeting a novel cytokine pathway implicated in autoimmune responses. As the pharmaceutical industry increasingly emphasizes personalized medicine, Measurin’s clinical profile and market potential warrant a thorough analysis of its clinical development trajectory, competitive positioning, and future market prospects.

Clinical Trials Update

Overview of Clinical Development Phases

Measurin has advanced through initial clinical testing stages, with its pivotal Phase 2 trials completed in late 2022. The ongoing Phase 3 studies commenced in Q2 2023, aiming to establish definitive efficacy and safety profiles required for regulatory approval. These pivotal trials are randomized, double-blind, placebo-controlled, enrolling approximately 1,200 patients across North America, Europe, and Asia.

Efficacy and Safety Data

Preliminary interim results from Phase 3 data, presented at the International Congress of Rheumatology in early 2024, indicate significant improvement in disease activity scores compared to placebo. Specifically, the proportion of patients achieving ACR50 response (a 50% improvement in RA symptoms) exceeds 70% at 12 weeks, surpassing benchmarks set by existing biologics [1].

Safety profiles remain consistent with earlier phases; adverse events are predominantly mild or moderate, with transient infusion reactions and gastrointestinal disturbances most common. Serious adverse events (SAEs) are rare (<2%) and comparable to existing therapies.

Regulatory Outlook

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted Breakthrough Therapy Designation (BTD) and Priority Review status, respectively, reflecting high clinical promise and the urgent necessity for novel RA treatments. Submission of New Drug Applications (NDAs) is targeted for Q4 2024, with potential approval timelines within 12–18 months depending on review outcomes.

Market Analysis

Current Treatment Landscape

Rheumatoid arthritis affects approximately 1% of the global population, with an estimated 20 million patients worldwide. The therapeutic landscape is heavily reliant on biologic disease-modifying antirheumatic drugs (bDMARDs) such as adalimumab, etanercept, and infliximab, which collectively generate over $30 billion annually (2019 metric) [2]. Despite their efficacy, biologics are associated with high costs, injection-site reactions, and immunogenicity issues, creating a market gap for alternative therapies.

Unmet Medical Needs and Market Drivers

Measurin aims to fulfill unmet needs—particularly oral administration options and improved safety profiles—by offering a potentially convenient, well-tolerated, and effective treatment. The growing patient preference for oral small molecules over injectable biologics aligns with the trend toward oral DMARDs, expanding market accessibility.

Additionally, increased awareness of treatment adherence and the proliferation of biosimilar options heighten demand for innovative therapies with superior efficacy and safety. The aging population and rising prevalence of RA in Asia and the Middle East further broaden the market scope.

Competitive Landscape

Major competitors include:

• AbbVie’s Humira (adalimumab) and other anti-TNF agents.
• Roche’s Actemra (tocilizumab) targeting IL-6 pathways.
• Pfizer’s Xeljanz (tofacitinib)—a leading oral Janus kinase (JAK) inhibitor.
• Eli Lilly’s Olumiant (baricitinib).

Measurin’s differentiation hinges on its novel cytokine target and the feasibility of oral delivery, potentially disrupting existing biologic-dependent paradigms.

Market Penetration and Revenue Projections

Assuming successful regulatory approval in 2025, initial market penetration could accrue approximately $500 million in sales within the first two years, driven by accelerated adoption among biologic-naïve patients and those intolerant to existing therapies.

Long-term projections estimate a compound annual growth rate (CAGR) of ~12%, reaching $2 billion in annual revenue by 2030, contingent upon favorable safety, efficacy, and pricing strategies.

Market Challenges and Opportunities

Challenges

• Pricing and reimbursement: High-cost biologics dominate, and negotiations with payers could limit Measurin’s pricing flexibility.
• Competition: Several pipeline candidates with similar targets are entering Phase 2, potentially diluting market share.
• Regulatory hurdles: Any delays or additional data requests could postpone market entry.

Opportunities

• Combination therapies: Potential synergies with existing DMARDs could expand indications.
• Expansion into other autoimmune conditions: Investigations into psoriatic arthritis and ankylosing spondylitis are underway.
• Enhanced patient adherence: Oral administration could substantially increase global market penetration.

Projection Summary

Given current clinical milestones, regulatory momentum, and an expanding unmet medical market, Measurin’s commercial prospects are robust. A conservative estimate suggests achieving a peak global sales figure of approximately $2.5 billion by 2030, underpinned by differentiated efficacy and safety advantages.

Key Takeaways

• Clinical advancement positions Measurin as a promising candidate with significant efficacy signals and a favorable safety profile.
• Regulatory designations facilitate expedited review, potentially accelerating time-to-market.
• The global RA market remains highly lucrative, with unmet needs aligning with Measurin’s strengths.
• Pricing, reimbursement, and competitive threats could influence market penetration but also present opportunities for strategic differentiation.
• Expansion into broader autoimmune indications could diversify revenue streams and enhance long-term growth.

FAQs

1. When is Measurin expected to receive regulatory approval?
Regulatory submissions are planned for Q4 2024, with approval anticipated within 12–18 months, depending on review outcomes.

2. How does Measurin differ from existing RA therapies?
Measurin targets a novel cytokine pathway, with its oral administration offering a significant advantage over injectable biologics, alongside a promising safety profile.

3. What are the main risks facing Measurin’s commercial success?
Potential risks include regulatory delays, high pricing pressures, aggressive competition, and unforeseen safety issues emerging in larger populations.

4. Could Measurin be used for other autoimmune diseases?
Yes, ongoing research aims to evaluate its efficacy in conditions such as psoriatic arthritis, ankylosing spondylitis, and potentially other inflammatory diseases.

5. What is the strategic significance of Measurin’s clinical performance?
Strong clinical data enhances its market positioning, supports favorable regulatory decisions, and increases investor confidence, ultimately influencing valuation and partnering opportunities.

---

Sources

[1] International Congress of Rheumatology, 2024. "Phase 3 Measurin Trial Data."

[2] IQVIA. "Global Rheumatoid Arthritis Market Insights," 2019.